Bay Area biotech firm once worth billions guts staff with 73% layoff
IGM Biosciences lays off 73% of staff due to poor clinical study results and aims to preserve cash amid ongoing research challenges.
Calif. biotech company that raised $325 million shuts down, lays off all workers
EFFECTOR Therapeutics, a biotech company focusing on cancer research, is shutting down after failing to bring a product to market despite raising significant funds.
HERVolution Therapeutics Raises $11.7M Series A to Advance Dark Genome-Based Immunotherapies for Cancer and Aging
HERVolution secures $11.7 million Series A funding to advance HERV-targeting immunotherapies.
Struggling Bay Area biotech firm, once worth $1B, lays off almost entire staff
Kronos Bio is undergoing major layoffs and has discontinued its only clinical drug due to adverse effects.
Bay Area biotech firm once worth billions guts staff with 73% layoff
IGM Biosciences lays off 73% of staff due to poor clinical study results and aims to preserve cash amid ongoing research challenges.
Calif. biotech company that raised $325 million shuts down, lays off all workers
EFFECTOR Therapeutics, a biotech company focusing on cancer research, is shutting down after failing to bring a product to market despite raising significant funds.
HERVolution Therapeutics Raises $11.7M Series A to Advance Dark Genome-Based Immunotherapies for Cancer and Aging
HERVolution secures $11.7 million Series A funding to advance HERV-targeting immunotherapies.
Struggling Bay Area biotech firm, once worth $1B, lays off almost entire staff
Kronos Bio is undergoing major layoffs and has discontinued its only clinical drug due to adverse effects.
Diverse NYC startup fundings and events include Gameto's $33M biotech raise, Authentic Insurance's $11M, Matter Bio's $7M, and Clasp's $6.4M funding.
A surfer without a degree is worth $16 billion after his biotech company's stock soared 1,100% in a year
Bob Duggan, an uneducated entrepreneur, became a biotech billionaire through Summit Therapeutics, exemplifying success outside traditional academic pathways.
Why a silly-sounding name suits the serious mission of our biotech spin-off
Richard Kuo's journey from a genomics PhD student to CEO of Wobble Genomics illustrates the growth potential in biotech entrepreneurship.
The aftermath of Theranos's failure has made biotech funding riskier, impacting new startups' abilities to secure investments.
Starting up right: Yasin Qureshi's advice for aspiring FinTech and Biotech entrepreneurs - London Business News | Londonlovesbusiness.com
Yasin Qureshi advocates for strategic distribution and funding as essential elements for success in FinTech and Biotech.
#NYCtech Week in Review: 5/26/24 - 6/1/24
Diverse NYC startup fundings and events include Gameto's $33M biotech raise, Authentic Insurance's $11M, Matter Bio's $7M, and Clasp's $6.4M funding.
A surfer without a degree is worth $16 billion after his biotech company's stock soared 1,100% in a year
Bob Duggan, an uneducated entrepreneur, became a biotech billionaire through Summit Therapeutics, exemplifying success outside traditional academic pathways.
Why a silly-sounding name suits the serious mission of our biotech spin-off
Richard Kuo's journey from a genomics PhD student to CEO of Wobble Genomics illustrates the growth potential in biotech entrepreneurship.
The aftermath of Theranos's failure has made biotech funding riskier, impacting new startups' abilities to secure investments.
Starting up right: Yasin Qureshi's advice for aspiring FinTech and Biotech entrepreneurs - London Business News | Londonlovesbusiness.com
Yasin Qureshi advocates for strategic distribution and funding as essential elements for success in FinTech and Biotech.
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
Verdiva has raised $410 million to develop oral drugs for obesity, challenging established players by addressing unmet medical needs in weight loss.
Triveni Bio Raises $115M Series B Financing to Advance Antibody Treatments for I&I Disorders
Triveni Bio Inc. raised $115 million to accelerate its antibody therapies for immune and inflammatory disorders, focusing on novel pathways and advanced treatment efficacy.
French biotech Generare speeds up hunt for new drugs by cloning natural molecules | TechCrunch
Generare raised €5 million to enhance its scalable methods for discovering natural compounds for drug development.
Visibuilt Raises 1.3 Million to Transform Asphalt Production with Mycelium
Visibuilt raises €1.3 million to develop visiBIT, a sustainable binder that could replace traditional bitumen in asphalt production and reduce CO2 emissions.
Cradle has raised $73M in Series B funding to expand AI capabilities in protein engineering, totaling over $100M raised to date.
In other news this week: Voiceline secures 2.4M, FRVR bags 11.5M, YC's Cosine codifies human reasoning and more - Silicon Canals
This week saw startups securing significant funding in tech, energy, and biotech sectors, focusing on innovative solutions and sustainable practices.
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
Verdiva has raised $410 million to develop oral drugs for obesity, challenging established players by addressing unmet medical needs in weight loss.
Triveni Bio Raises $115M Series B Financing to Advance Antibody Treatments for I&I Disorders
Triveni Bio Inc. raised $115 million to accelerate its antibody therapies for immune and inflammatory disorders, focusing on novel pathways and advanced treatment efficacy.
French biotech Generare speeds up hunt for new drugs by cloning natural molecules | TechCrunch
Generare raised €5 million to enhance its scalable methods for discovering natural compounds for drug development.
Visibuilt Raises 1.3 Million to Transform Asphalt Production with Mycelium
Visibuilt raises €1.3 million to develop visiBIT, a sustainable binder that could replace traditional bitumen in asphalt production and reduce CO2 emissions.
Cradle builds out its protein-design AI platform (and wet lab) with $73M in new funding | TechCrunch
AI is rapidly transforming biotech, with companies like Cradle leading the charge in protein design and development.
Hollywood's Olivia Wilde launches a VC firm | TechCrunch
Olivia Wilde launches Proximity Ventures, targeting early and growth-stage investments in consumer and enterprise sectors.
Biotech startup Cradle raises $73 million in investment round
Cradle raised $73 million to enhance its AI platform for protein development, aiming to optimize DNA sequences and scale operations.
Dutch immunotherapy company Pan Cancer T bags 4.2M - Silicon Canals
Rotterdam-based Pan Cancer T secured €4.25M in seed extension, advancing T cell therapies for solid cancers, with support from new and existing investors.
Cradle builds out its protein-design AI platform (and wet lab) with $73M in new funding | TechCrunch
AI is rapidly transforming biotech, with companies like Cradle leading the charge in protein design and development.
Hollywood's Olivia Wilde launches a VC firm | TechCrunch
Olivia Wilde launches Proximity Ventures, targeting early and growth-stage investments in consumer and enterprise sectors.
Biotech startup Cradle raises $73 million in investment round
Cradle raised $73 million to enhance its AI platform for protein development, aiming to optimize DNA sequences and scale operations.
Dutch immunotherapy company Pan Cancer T bags 4.2M - Silicon Canals
Rotterdam-based Pan Cancer T secured €4.25M in seed extension, advancing T cell therapies for solid cancers, with support from new and existing investors.
Everything to know about Vivek Ramaswamy, co-lead of the Department of Government Efficiency with Elon Musk
Vivek Ramaswamy's transition from a failed presidential bid to a key position in Trump's government highlights his rapid ascent in political influence.
Other Barks & Bites for Friday, October 18: OpenAI Outlines Defensive Patent Strategy; Microsoft Files Opposition in Lawsuit Alleging Illegal Buyer's Cartel for Patent Licenses; Moderna Under Fire for Spikevax Vaccine Tech
Trilobio wins injunction in a trade secret case against a former employee, underscoring the importance of IP protection in biotech.
Prolific Machines, with a $55M Series B, shines 'light' on a better way to grow lab proteins for food and medicine | TechCrunch
Prolific Machines has developed a bioreactor using light to control cell growth, aiming to revolutionize manufacturing of cultivated meat and medicine.
Many scientists are neurodivergent. Architects are finally starting to build labs designed for them
Traditional lab designs may inhibit research by not accommodating the diverse needs of neurodivergent scientists.
Prolific Machines, with a $55M Series B, shines 'light' on a better way to grow lab proteins for food and medicine | TechCrunch
Prolific Machines has developed a bioreactor using light to control cell growth, aiming to revolutionize manufacturing of cultivated meat and medicine.
Many scientists are neurodivergent. Architects are finally starting to build labs designed for them
Traditional lab designs may inhibit research by not accommodating the diverse needs of neurodivergent scientists.
Exclusive: Connected fitness startup EGYM is ramping up with $200m at a $1.2B+ valuation
EGYM secures over $200 million funding to expand tech-driven fitness solutions in new markets and enhance AI-based training tools.
Exclusive: Synex founder, once detained at the border with a 80-pound magnet, is building portable MRIs to test glucose
Synex Medical is developing a portable MRI for non-invasive glucose testing, potentially revolutionizing diabetes care.
Lyon-based Brenus Pharma secures 22.2M to advance cancer vaccine trials: Here's how - Silicon Canals
Brenus Pharma secures €22.2M Series A funding to advance cancer vaccine development, targeting metastatic colorectal cancer and expanding into other gastric tumors.
3 Penny Stocks To Buy With Just $50
Investing in penny stocks can yield high returns, but risks must be carefully managed.
A newly built office tower in downtown Durham is turning to speculative lab space
Developers are adapting to increased vacancy rates by creating lab space to attract tenants.
Roxboro's speculative lab spaces aim to support smaller biotech firms amidst leasing challenges.
Building a culture of GxP excellence in biotech - London Business News | Londonlovesbusiness.com
GxP is essential not only for compliance but for embedding product safety and public trust into the core operations of biotech organizations.
Tech and biotech layoffs jolt Bay Area with hundreds of lost jobs
The ongoing layoffs in Bay Area tech and biotech sectors reflect a troubling trend, with over 45,700 jobs cut since 2022.
Startups Weekly: What goes up must come down | TechCrunch
Microsoft absorbs Inflection, leaving it in a precarious position
Microbiome startups may lack scientific rigor
This futurist predicts that everybody will have an AI digital twin
Super cycles are extended periods of booming demand driven by structural change.
Current super cycle is propelled by AI, biotech, and wearables leading to reshaping of human civilization.
A Pill That Kills Ticks Is a Promising New Weapon Against Lyme Disease
A human pill for tick prevention like those for pets is in development by Tarsus Pharmaceuticals.
The pill showed in a trial to kill ticks on people and provide protection for up to 30 days.
What's News, Breaking: Friday, February 2, 2024
A new biotech workforce development program launched in New York City, offering training and career development opportunities in the rapidly growing biotechnology sector.
The program is open to individuals pursuing employment in the life sciences ecosystem, even if they don't have backgrounds in STEM.
San Jose tech and biotech incubator hub gains traction and tenants
BioCube in San Jose attracts tech and biotech companies, provides a complete ecosystem for startups to grow in place.
How gene-therapy treated mice in space may help shape the science of vision loss diseases
Biotech Oculogenex received FDA endorsement for therapy in treating eye-wasting disease.